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sist Device. An increasing number of patients have a coexisting implantable cardioverter defibrillator
(ICD) and left ventricular assist device (LVAD) to treat ventricular arrhythmias and refractory heart fail-
ure, respectively. To date, there have been no published reports of negative interactions between these
devices that have impacted appropriate ICD or LVAD function. In this case report, we describe a patient
with an LVAD-ICD interaction that necessitated replacement of the implantable defibrillator. (J Cardiovasc
Electrophysiol, Vol. 18, pp. 1107-1108, October 2007)
clinical, implantable devices, ventricular tachycardia/fibrillation clinical, electrophysiology, ventricular
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Introduction
Implantation of a left ventricular assist device as a bridge to
cardiac transplantation or as destination therapy for patients
with end stage heart failure is becoming increasingly com-
mon. In 2005, approximately 1100 LVADs were implanted
in the United States (personal communication with Thoratec,
May 2006). Because recent clinical trials have demonstrated
the survival benefit of implantable cardioverter defibrillators
in patients with heart failure, many LVAD candidates have an
ICD in place prior to LVAD surgery.1,2 While the discharge of
an ICD has not been found to impair the mechanical function
of contemporary LVADs, little has been published about the
impact of electromagnetic interference from LVADs on ICD
function. This case report describes a patient with an interac-
tion between his ICD and HeartMate II LVAD that resulted
in an inability to interrogate and program the ICD, ultimately
requiring replacement of the ICD.
Case Report
A 48-year-old man presented to an outside institution in
February, 2006, with an acute anterior myocardial infarction.
Cardiac catheterization revealed a left ventricular ejection frac-
tion of 0.10 and occlusion of the left anterior descending and
right coronary arteries. A drug-eluting stent was deployed in
the left anterior descending artery. His hospital stay was compli-
cated by recurrent ventricular tachycardia (VT). He was treated
with intravenous amiodorone and underwent implantation of
a single-chamber nonthoracotomy implantable cardioverter
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defibrillator (Model V193; St. Jude Medical Corporation, Sun-
nyvale, CA, USA) in the left prepectoral position.
Five days after discharge from the hospital, the patient pre-
sented to an outside facility in cardiogenic shock with recurrent
ICD therapies requiring reinitiation of intravenous amiodarone.
Interrogation of his ICD revealed normal device function, with
appropriate shocks delivered for recurrent episodes of ventric-
ular tachycardia. He was discharged from the hospital three
weeks later, with oral amiodarone added to his medical regi-
men.
On April 2, 2006, the patient again presented with recurrent
ICD shocks for ventricular tachycardia and was transferred
to the University of Michigan Health System for management
of his ischemic cardiomyopathy and arrhythmias. During this
admission, defibrillation testing demonstrated normal defib-
rillator function with a defibrillation energy requirement of
≤10 Joules. A lack of significant myocardial viability on per-
fusion imaging and the severe degree of left ventricular dys-
function with hemodynamic derangements led to recommen-
dations for placement of an LVAD as a bridge to cardiac
transplantation.
On April 21, 2006, the patient was taken to the operating
room for placement of an LVAD. Immediately prior to surgery,
his ICD was interrogated and again demonstrated normal de-
vice function. Ventricular tachycardia therapies were then dis-
abled. The patient underwent uncomplicated placement of a
HeartMate II left ventricular assist device (Thoratec Corpora-
tion, Pleasanton, CA, USA). Post-operatively, the HeartMate II
pump speed was set at 9400 rpm to provide adequate device
flow, pulsatility index, and hemodynamic status. When the elec-
trophysiology team attempted to interrogate and reprogram the
ICD following surgery, telemetry between the ICD and the de-
fibrillator programmer could not be established, despite using
multiple programmers and programming head positions. Based
on recommendations from the ICD manufacturer, six inches of
towels were placed over the ICD pocket while the LVAD pump
speed was maintained at 9400 rpm. Again, telemetry between
the ICD and the programmer was unsuccessful.
Because of the inability to interrogate or reprogram the
patient’s ICD at the optimal LVAD speed, the ICD generator
was removed and replaced with another manufacturer’s ICD
(Medtronic Inc., Minneapolis, MN, USA). After implantation of
the new ICD, programmer-ICD telemetry was established with
normal interrogation and programming of the ICD at LVAD
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speeds of 9000–10,000 rpm. Interrogation of the explanted St.
Jude ICD was successful and revealed otherwise normal device
function.
Discussion
In the 20 years of LVAD use, this case report represents the
first description of an adverse interaction between an LVAD
and an ICD requiring replacement of the ICD. In this patient,
an adverse interaction with the HeartMate II LVAD prevented
telemetry communication between the device programmer
and the St. Jude ICD. Intrinsic malfunction of the ICD or
its programmer is very unlikely, since both devices func-
tioned normally in the absence of the LVAD. Other sources
of electromagnetic interference were considered, but the ICD
demonstrated normal interrogation and programming in the
same environments both before the LVAD implant and af-
ter the St. Jude ICD was removed. Potential causes for the
problem include electromagnetic frequencies produced dur-
ing LVAD operation that are similar to the telemetry frequen-
cies used during ICD interrogation, and programming. An-
other possibility is that the current shielding available in the
ICD is insufficient to prevent electromagnetic interference
from the LVAD that is placed in proximity to the ICD.
At the University of Michigan Health System, with over
200 LVAD implants to date, this is the first occurrence of
an ICD-LVAD interaction. Of the 80 patients implanted with
an LVAD device (53% HeartMate I, 35% HeartMate II, 12%
other) at our institution since May 2003, 53 (66%) had a
preexisting ICD in place at the time of LVAD surgery. Manu-
facturer data was available on 45 of the 53 ICDs, and 53% (n
= 24) were Medtronic, 40% (n = 18) were Boston Scientific
(St. Paul, MN), 4.4% (n = 2) were Biotronik (Lake Oswego,
OR), and 2.2% (n = 1) were St. Jude.
The St. Jude Corporation acknowledged previous unpub-
lished instances of similar problems with ICD interrogation
and reprogramming in patients after HeartMate II implan-
tation (personal communication with St. Jude Corporation,
May 2006). According to the company, the malfunction is
caused by electromagnetic interference from the HeartMate
II LVAD, impairing telemetry communication between the
ICD and the ICD programmer. They also reported that while
enabled ICDs function normally in the presence of the Heart-
Mate II, the defibrillator may not be able to be interrogated
or programmed while the LVAD functioned at the prescribed
speeds. St. Jude also reports that the telemetry frequencies
for their implantable pacemakers are similar to that of their
ICDs.
Other options suggested by St. Jude Medical were to ei-
ther reduce the HeartMate II pump speed to 1300 rpm or
to increase the pump speed to 11,200–12,000 rpm. How-
ever, large changes in HeartMate II pump speeds, even if
only transient, could be detrimental to the patient. A reduc-
tion in LVAD pump speed to 1300 rpm for the few minutes
required to complete an interrogation could lead to hemo-
dynamic compromise and even syncope in patients with se-
vere intrinsic left ventricular dysfunction. Similarly, elevated
rotary speeds could quickly reduce left ventricular preload,
resulting in poor device flows and clinical decompensation.
The Thoratec Corporation does not recommend pump speeds
over 10,000 rpm with the HeartMate II.
The Thoratec Corporation stated that they were aware of
isolated instances of ICD malfunction in HeartMate II re-
cipients and that these problems appeared specific to ICDs
manufactured by the St. Jude Corporation (personal com-
munication with Thoratec Corporation, May 2006). Due to
the limited data available, it is unclear if ICDs from other
manufacturers could exhibit a similar interaction with the
HeartMate II. To date, there have been no reported adverse
ICD-LVAD interactions with either the Medtronic or Boston
Scientific ICDs. Likewise, it is unknown whether this de-
vice interaction is limited to the axial flow LVADs, such as
the HeartMate II, or if it can also occur with pulsatile flow
LVADs.
While an ICD is not routinely implanted in all patients
prior to LVAD surgery, reports describing the deleterious
hemodynamic and clinical effects of ventricular arrhythmias
in these patients support their use.3,4 With the increased use
of mechanical circulatory support, more ICD-LVAD interac-
tions may begin to appear. While St. Jude reports that their
new generation of devices (including the Atlas ICDs) op-
erate at a higher (4 Hz) frequency, allowing for successful
telemetry communication between the programmer and the
device during HeartMate II support, many LVAD candidates
may still have preexisting older St. Jude devices in place. In
patients undergoing LVAD evaluation, clinicians should con-
sider the potential for similar interactions between an ICD
or pacemaker and an LVAD, and take appropriate steps to
ensure that the device can be interrogated and programmed
normally after LVAD insertion.
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